Paliperidon Teva (Paliperidone Palmitate)

Paliperidon Teva is an antipsychotic medication that acts within the central nervous system to manage psychotic disorders.

• Schizophrenia: helps maintain symptom control and reduce relapse risk in adults.
• Schizoaffective disorder: contributes to stabilization of mood and psychotic symptoms.
• Bipolar I disorder (maintenance): assists in preventing recurrence of manic or depressive episodes when used as part of a broader treatment plan.

• Paliperidone palmitate is a long‑acting pro‑drug of paliperidone that, after intramuscular administration, is slowly hydrolysed to release paliperidone. The active moiety antagonises dopamine D2 and serotonin 5‑HT2A receptors, modulating neurotransmission in pathways implicated in psychosis and mood regulation.

Side effects reported with paliperidone palmitate vary in frequency and severity.

Common Side Effects

• Injection site pain or swelling.
• Weight gain.
• Fatigue or somnolence.
• Restlessness (akathisia).
• Constipation.
• Dry mouth.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome.
• Tardive dyskinesia.
• Severe orthostatic hypotension.
• Elevated prolactin leading to galactorrhea or menstrual disturbances.
• Seizure activity.
• Significant QT‑interval prolongation.
• Hyperglycaemia or new‑onset diabetes mellitus.

When prescribing Paliperidon Teva, clinicians should consider several safety aspects.

• Cardiovascular assessment: evaluate for history of arrhythmias or orthostatic hypotension.
• Metabolic monitoring: track weight, glucose, and lipid profiles regularly.
• Prolactin levels: monitor for signs of hyperprolactinaemia.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Elderly patients: start at lower doses and observe for sedation.
• Store at room temperature: keep in original packaging, protect from moisture and direct light.

Paliperidon Teva may interact with other medicines, requiring careful review.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – may increase paliperidone exposure.
• CNS depressants (e.g., benzodiazepines, opioids) – additive sedation.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents – may enhance orthostatic hypotension.

• Anticholinergic drugs – may worsen cognitive effects.
• Medications that prolong QT interval – increase risk of cardiac arrhythmias.
• CYP2D6 substrates – potential alteration of plasma levels.
• Herbal supplements (e.g., St. John’s wort) – may affect metabolism.